Alpine Woods Capital Investors’s Sarepta Therapeutics SRPT Stock Holding History

Alpine Woods Capital Investors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-3,000	Closed	-$226K	–	277
2019 Q3	$226K	Sell	3,000 -100	-3%	-$11.8K	0.04%	236
2019 Q2	$471K	Buy	+3,100	New	+$377K	0.1%	190
2018 Q4	–	Sell	-2,205	Closed	-$356K	–	296
2018 Q3	$356K	Buy	+2,205	New	+$301K	0.07%	178

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Alpine Woods Capital Investors's SRPT Position: Q4 2019 in Review

Alpine Woods Capital Investors sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 3,000 shares — an estimated $226K sold.

Alpine Woods Capital Investors first reported a position in SRPT in Q3 2018 and held it in 3 quarters. The position peaked at $471K in Q2 2019. 390 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

Alpine Woods Capital Investors reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
Alpine Woods Capital Investors sold 3,000 Sarepta Therapeutics shares in Q4 2019, an estimated $226K.
Alpine Woods Capital Investors first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 3 quarters.
Alpine Woods Capital Investors's Sarepta Therapeutics position peaked at $471K in Q2 2019.
390 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2019, filed 7 Feb 2020.